Ramucirumab (Synonyms: LY3009806) |
Catalog No.GC19534 |
Ramucirumab es un antagonista de VEGFR-2 humano para el tratamiento de tumores sÓlidos. Ramucirumab es un anticuerpo monoclonal de inmunoglobulina humana G1 recombinante que se une al dominio de uniÓn extracelular de VEGFR-2 y previene la uniÓn de los ligandos de VEGFR: VEGF-A, VEGF-C y VEGF-D. Ramucirumab también es un inhibidor de la angiogénesis.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 947687-13-0
Sample solution is provided at 25 µL, 10mM.
Ramucirumab is a fully human monoclonal antibody (IgG1). Ramucirumab is a direct VEGFR2 antagonist, that binds with high affinity to the extracellular domain of VEGFR2 and block the binding of natural VEGFR ligands (VEGF-A, VEGF-C and VEGF-D). These ligands are secreted by solid tumors to promote angiogenesis (formation of new blood vessels from pre-existing ones) and enhance tumor blood supply. Binding of ramucirumab to VEGFR2 leads to inhibition of VEGF-mediated tumor angiogenesis.
Average Rating: 5
(Based on Reviews and 29 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *